Luca Marcomigni

CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

Giulio Metro, Gianluigi Lunardi, Piero Floridi et al. · Journal of Thoracic Oncology · 2015 · 109 citations · Full text

Medicine, Oncology, Pharmacology +12

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

Giulio Metro, Rita Chiari, Simona Duranti et al. · Lung Cancer · 2012 · 70 citations

Medicine, Molecular Genetics, Oncology +16

Alectinib’s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series

Giulio Metro, Gianluigi Lunardi, Chiara Bennati et al. · Journal of Neuro-Oncology · 2016 · 26 citations

Medicine, Oncology, Pharmacology +14

Multiple EWSR1-WT1 and WT1-EWSR1 copies in two cases of desmoplastic round cell tumor

Roberta La Starza, Gianluca Barba, Valeria Nofrini et al. · Cancer Genetics · 2013 · 25 citations

Veterinary Medicine, Molecular Genetics, Oncology +14

Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation

Giulio Metro, Rita Chiari, M. Mare et al. · Cancer Chemotherapy and Pharmacology · 2011 · 19 citations

Medicine, Oncology, Pharmacology +16